|
|
Volumn 67, Issue 10, 2010, Pages 779-780
|
|
Clopidogrel poor metabolizers may need alternative to standard regimen
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID PLUS CLOPIDOGREL;
CLOPIDOGREL;
CYTOCHROME P450 2C19;
PRASUGREL;
ANTITHROMBOCYTIC AGENT;
CYP2C19 PROTEIN, HUMAN;
DRUG DERIVATIVE;
PRODRUG;
TICLOPIDINE;
UNSPECIFIC MONOOXYGENASE;
ALLELE;
ATHEROSCLEROSIS;
BLOOD CLOTTING PARAMETERS;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR EFFECT;
COHORT ANALYSIS;
DRUG LABELING;
DRUG METABOLISM;
FOOD AND DRUG ADMINISTRATION;
GENE MUTATION;
GENETIC SCREENING;
HEART INFARCTION;
HUMAN;
NOTE;
PHARMACOGENOMICS;
PRESCRIPTION;
PRIORITY JOURNAL;
RACE;
RETROSPECTIVE STUDY;
SIDE EFFECT;
STROKE;
THROMBOCYTE AGGREGATION;
TREATMENT OUTCOME;
ECONOMICS;
GENETICS;
GENOTYPE;
HEALTH CARE COST;
STANDARD;
ARYL HYDROCARBON HYDROXYLASES;
DRUG LABELING;
GENOTYPE;
HEALTH CARE COSTS;
HUMANS;
PLATELET AGGREGATION INHIBITORS;
PLATELET FUNCTION TESTS;
PRODRUGS;
TICLOPIDINE;
|
|
EID: 77956055385
PISSN: 10792082
EISSN: 15352900
Source Type: Journal
DOI: 10.2146/news100036 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
